Some pretty stupid and negative comments in here. I'm a long term holder and disappointed too. But that said, at least now all the bad news is out. The CE bogeyman is gone pretty much. Conditional approval is what it is. We are all forgetting the FDA IDE, which allows implant etc. There are no real treatments for pancreatic cancer, bar chemo.
Chemo is now better and the trials will imho be more successful than the last one. All future announcements likely positives...trials in UK, recruitment of patients, more ethics approvals, more hospitals and dosing of patients in next 5 months.
Why on earth would we still be there and sell now when the train has finally commenced moving from the station. imho I expect the market to reward this handsomely over the next 12 months. It will become a reality and with the quality of hospitals on board for the trial there will be a heck of a lot of trained physicians out there with recent data, experience in implanting and hence early adoption (remember no real alternatives in the space).
As someone said CE, SHmCE - no-one would have been trained in any case!
Madness to cut now. Top up on weakness and soak the loose hands. As OSL finally kicks some goals - the patience (frustrating I agree) - will be rewarded.
OSL Price at posting:
9.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)